Neogen Corporation

NASDAQ:NEOG

Medical - Diagnostics & Research

Healthcare
$11.08 +1.79%

+$0.16 today

Market cap
$2.42B
Beta
1.80
P/E (TTM)
-3.3
EPS (TTM)
-$2.80
52W Low $4.56High $11.43

Volume 1.79M

Average 2.53M

NEOG Other Working Capital

Cash effect of changes in other operating assets and liabilities.

Neogen CorporationNASDAQ: NEOG

Other Working Capital · Q1 FY2027 · quarter ended Aug 2026

Other working capital growth accelerates

Q1 FY2027 other working capital of $10.5M (cash outflow) rose 25.8% year over year, ahead of the -3805.0% change in trailing-twelve-month other working capital.

Context

  • Other working capital amounted to 0.7% of revenue in FY2026, up 0.6 pp from a year earlier.
  • Other working capital increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +25.8% holds above the trailing-twelve-month pace of -3805.0%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterAug 2026
-$10.5M-192.9% QoQ
Last fiscal yearMay 2026
-$6M+470.9% YoY
LTMAug 2026
-$8.15M-3805.0% YoY
Other Working Capital past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+25.8%——
1 year+470.9%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Working Capital history

USD · from the cash flow

Latest · FY2026
(6M) USD
Year-over-year change
-470.9%

Other Working Capital vs competitors

How NEOG compares with its peers on the latest reported figures

  • NEOG's LTM Aug 2026 other working capital of $8.15M is the 5th largest of the 7 companies compared; the peer median is $122.67M.
  • Its year-over-year change of -3805.0% is the lowest of 7, against a peer median of +76.5%.
  • Other working capital amounts to 0.9% of revenue for NEOG, versus a peer median of 1.4%.
NEOG Competitors Peer median
Other Working Capital for NEOG and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MRKMerck & Co., Inc.LTM Jun 2026$1.02B +119.4%+41.8%1.5%
ZTSZoetis Inc.LTM Jun 2026$332M +39.5%-26.1%3.5%
ELANElanco Animal Health IncorporatedLTM Sep 2026$225M +144.6%—4.4%
PAHCPhibro Animal Health CorporationLTM Mar 2026$20.34M -45.5%—1.4%
NEOGNeogen CorporationLTM Aug 2026$8.15M -3805.0%—0.9%
BCPCBalchem CorporationLTM Sep 2026$5.98M -167.9%—0.5%
IDXXIDEXX Laboratories, Inc.LTM Sep 2026$5.3M +113.6%+9.5%0.1%
Peer median (excluding NEOG) $122.67M+76.5%+9.5%1.4%

Competitors are the stored peer set for NEOG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2022
May 2022
FY2023
May 2023
FY2024
May 2024
FY2025
May 2025
FY2026
May 2026
Net Income48.31M(22.87M)(9.42M)(1.09B)(7.9M)
Depreciation & Amortization24.13M90.47M121.23M125.67M116.3M
Deferred Income Tax(4.7M)(19.23M)(27.42M)(57.78M)(24.3M)
Stock-Based Compensation7.15M10.18M13.77M17.29M13.4M
Change in Working Capital(4.42M)(24.2M)(72.68M)(5.93M)58.8M
Accounts Receivables(7.8M)(53.88M)(20.1M)11.64M6.8M
Inventory(21.07M)9.96M(55.95M)(16.12M)38.2M
Accounts Payables20.24M18.64M13.75M(402K)19.8M
Other Working Capital4.21M1.09M(10.38M)(1.05M)(6M)
Other Non-Cash Items(2.44M)6.67M9.8M1.07B(73.1M)
Operating Cash Flow68.04M41.03M35.26M58.24M83.2M
Capital Expenditures(24.43M)(65.76M)(111.42M)(104.6M)(51.3M)
Acquisitions (Net)(38.75M)12.55M108K5.08M121.7M
Purchases of Investments(415.89M)(12.52M)000
Sales of Investments381.84M266.77M82M325K0
Other Investing Activities0000100K
Investing Cash Flow(97.23M)201.04M(29.31M)(99.2M)70.5M
Debt Repayment0(100M)(420K)(321K)(100M)
Common Stock Issued7.93M1.2M2.46M2.24M1.6M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(1.12M)(19.28M)(118K)(3.52M)(1M)
Financing Cash Flow6.81M(118.08M)1.92M(1.6M)(99.4M)
Effect of Forex Changes(8.75M)(5.22M)(502K)942K2.2M
Net Change in Cash(31.13M)118.77M7.37M(41.61M)56.5M
Free Cash Flow43.61M(24.73M)(76.16M)(46.35M)31.9M

Neogen Corporation

NASDAQ:NEOG

Intrinsic Alpha fair value

Locked

Current Price

$11.08

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.